Eli Lilly enters global license agreement with OliX for OLX75016
OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and ...
Contract Pharma2d
OliX, Lilly Enter Global Licensing Agreement for Cardiometabolic Indications
To develop OliX’s OLX75016 candidate primarily targeting metabolic-associated steatohepatitis (MASH).
Nature4y
Driving drug development through next-generation oligonucleotide technology
OliX Pharmaceuticals, the first Asian company to advance its own proprietary RNA interference (RNAi) technology platform into the clinic, is using RNAi technology to treat skin, eye and lung ...
Yahoo Finance4d
OliX and Lilly Enter Global Licensing Agreement for MASH and Other Cardiometabolic Indications
SEONGNAM, South Korea, February 10, 2025--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a global licensing agreement with ...